P-265 Mezigdomide (MEZI) monotherapy in relapsed/ refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial

Scott Goldsmith; Albert Oriol; Pekka Anttila; Nizar J. Bahlis; Jesús G. Berdeja; Andrew J. Cowan; Meletios A Dimopoulos; Laahn Foster; Jens Hillengaß; Martha Louzada; Ka Lung Wu; Tracy Chow; Wen‐Cong Chen; Yue Wang; Alessia Spirlì; Phillip J. Koo; Paulo Maciag; Daniel Zhu; Jessica Katz; Paul G. Richardson

doi:10.1016/s2152-2650(23)01883-9

Related publications

Article2025

MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial

Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab

Article2024

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard LeBlanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab

Article2022

OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Paul G. Richardson, Irwindeep Sandhu, Albert Oriol, Marc S. Raab, Darrell White, Richard Leblanc, Aurore Perrot, Enrique M. Ocio, Noopur Raje, Charlotte Toftmann Hansen, Ze‐Hua Zhou, Tiziana Civardi, Alessandro Ghiddi, Jessica Katz, Teresa Peluso, Meletios A Dimopoulos

Article2025

Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial

Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier Leleu, Samuel M. Rubinstein, Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández-de Larrea, Aurora Breazna, James Drew, Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero

Article2025

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.

Paula Rodríguez‐Otero, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Salomon Manier, Carmen Martínez‐Chamorro, Rajshekhar Chakraborty, Sam Rubinstein, Anna Sureda, Marta Sonia González, Jean‐Marie Michot, Aurora Breazna, James Drew, Anita Boyapati, Sheila Masinde, Glenn S. Kroog, Shawn Sarkaria, Joaquín Martínez‐López

P-265 Mezigdomide (MEZI) monotherapy in relapsed/ refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial

Discussion(0)

Related publications

MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.